Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 16/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31217014 | 1.00 | KRAS (0.43) | KRASUSP30PIK3CAMTORPIK3R1 | |
| SCHEMBL23909725 | 1.00 | KRAS (0.43) | KRASUSP30PIK3CAMTORPIK3R1 | |
| SCHEMBL31217079 | 0.92 | KRAS (0.50) | KRAS | |
| SCHEMBL21662916 | 0.92 | KRAS (0.50) | KRAS | |
| SCHEMBL23909812 | 0.91 | KRAS (0.41) | KRASUSP30PIK3CA | |
| SCHEMBL31217138 | 0.91 | KRAS (0.41) | KRASUSP30PIK3CA | |
| SCHEMBL23909815 | 0.91 | KRAS (0.41) | KRASUSP30PIK3CA | |
| SCHEMBL21662825 | 0.90 | KRAS (0.42) | KRASUSP30PIK3CAPIK3R1 | |
| SCHEMBL23909806 | 0.90 | KRAS (0.42) | KRASUSP30PIK3CAPIK3R1 | |
| SCHEMBL31217166 | 0.90 | KRAS (0.42) | KRASUSP30PIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | KRAS, NRAS, HRAS | KRAS 1/4885USP30 4690/4885PIK3CA 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.